Insider Selling: Exelixis, Inc. (NASDAQ:EXEL) EVP Sells 25,000 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 25,000 shares of the company’s stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $46.18, for a total transaction of $1,154,500.00. Following the sale, the executive vice president now owns 693,396 shares of the company’s stock, valued at $32,021,027.28. The trade was a 3.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Exelixis Trading Down 1.9%

EXEL stock opened at $45.40 on Friday. The stock has a 50-day moving average price of $37.23 and a two-hundred day moving average price of $35.82. The stock has a market cap of $12.51 billion, a PE ratio of 25.65, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25. Exelixis, Inc. has a 1 year low of $20.14 and a 1 year high of $48.85.

Hedge Funds Weigh In On Exelixis

A number of large investors have recently added to or reduced their stakes in the company. Frank Rimerman Advisors LLC increased its holdings in Exelixis by 4.7% during the 1st quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 285 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in Exelixis by 18.1% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 290 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in Exelixis by 6.1% during the 1st quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 307 shares in the last quarter. Balyasny Asset Management L.P. increased its holdings in Exelixis by 1.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company’s stock worth $573,000 after purchasing an additional 317 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in shares of Exelixis by 4.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock worth $235,000 after buying an additional 330 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on EXEL shares. Royal Bank of Canada reiterated an “outperform” rating and set a $40.00 target price on shares of Exelixis in a research report on Wednesday. UBS Group reiterated an “underperform” rating on shares of Exelixis in a research report on Thursday, April 17th. Stifel Nicolaus upped their target price on shares of Exelixis from $36.00 to $38.00 and gave the company a “hold” rating in a research report on Wednesday. Citigroup upped their target price on shares of Exelixis from $45.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Wells Fargo & Company reiterated a “market outperform” rating on shares of Exelixis in a research report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and an average target price of $38.76.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.